|
1 Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormoneof the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, compound 8E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin,1949, 24:181-197.
|
|
2 Schwartzman RA, Cidlowski JA. Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocr Rev, 1993, 14(2): 133-151.
|
|
3 Pallardy M, Biola A. Induction of apoptosis in lymphocytes by glucocorticoids: Between physiology and pharmacology. C R Seances Soc Biol Fil, 1998,192(6):1051-1063.
|
|
4 Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: Promotion of a Th2 cytokine-secreting profile. Clin Transplant, 1999, 13(5): 365-374.
|
|
5 杨海平. 酷似皮下脂膜炎的T细胞淋巴瘤. 国外医学皮肤性病学分册,1997, 23(6):325-329.
|
|
6 金有豫主编. 药理学. 北京:人民卫生出版社,2001, 285-292.
|
|
7 Liu RY, Unmehopa UA, Zhou JN, et al. Glucocorticoids suppress vasopressin gene expression in human suprachiasmatic nucleus. J Steroid Biochem Mol Biol, 2006, 98(4-5):248-253.
|
|
8 Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: A systematic review of RCTs. BMC Pediatr, 2001,1:1.
|
|
9 Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol, 2000, 16(4):505-511.
|
|
10 Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther, 2002, 96(1):23-43.
|
|
11 Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med, 2004, 141(10): 764-770.
|
|
12 Libby P. Inflammation in atherosclerosis. Nature, 2002, 420: 868-874.
|
|
13 Makheja AN, Bloom S, Muesing R, et al. Anti-inflammatory drugs in experimental atherosclerosis.7.Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis, 1989, 76(2-3): 155-161.
|
|
14 Hagashi H, Nomoto A, Mutoh S, et al. Role of inflammatory responses in initiation of atherosclerosis: Effects of anti-inflammatory drugs on cuff-induced leukocyte accumulation and intimal thickening of rabbit carotid artery. Atherosclerosis, 1991, 91(1-2): 107-116.
|
|
15 Villa AE, Guzman LA, Chen W, et al. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest, 1994, 93(3):1243-1249.
|
|
16 Libby P, Maroko PR, Bloor CM, et al. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest,1973, 52:599-607.
|
|
17 Spath JA Jr, Lane DL, Lefer AM. Protective action of methylprednisolone on the myocardium during experimental myocardial ischemia in the cat. Circ Res,1974, 35(1): 44-51.
|
|
18 Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum, 1998, 41(5): 761.
|
|
19 Bamberger CM, Bamberger AM, de Castro M, et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest, 1995, 95(6): 2435-2441.
|
|
20 Youssef PP, Cormack J, Evill CA, et al. Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Arthritis Rheum, 1996, 39(2): 216.
|
|
21 Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaledcorticosteroids for persistent asthma. J Allergy Clin Immunol, 2002, 109(3): 410-418.
|
|
22 Kofler R, Schmidt S, Kofler A, et al. Resistance to glucocorticoid-induced apoptosisin lymphoblastic leukemia. J Endocrinol, 2003, 178(1): 19-27.
|
|
23 Oakley RH, Jewell CM,Yudt MR, et al. The dominant negative activity of the human glucocorticoid receptor beta isoform.Specificity and mechanism of action. J Biol Chem,1999, 274:27857-27866.
|
|
24 Sousa AR, Lane SJ, Clidllowski JA, et al. Glucocorticoid resistance in asthma is associated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol, 2000,105(5): 943-950.
|
|
25 Chikanza IC. Mechanisms of corticosteroid resistance in rheumatoid arthritis: A putative role for the corticosteroid receptor beta isoform. Ann NY Acad Sci, 2002, 966: 39-48.
|
|
26 Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid - resisitant ulcerative colitis.Gastroenterology, 2000,118: 859-866.
|
|
27 Galiardo R, Chanez P, Vignola AM, et al.Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med, 2000, 162(1): 7-13.
|
|
28 McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and thesteroid hormone receptors: Mechanisms of mutual antagonism. Mol Endocrinol,1998,12(1): 45-56.
|
|
29 Adcock IM, Lane SJ, Brown CR, et al. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med, 1995, 182(6):1951-1958.
|
|
30 Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest, 1994, 93(1): 33-39.
|
|
31 Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg, 2000, 37(8): 581-584.
|
|
32 Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas followingprednisolone therapy. Plast Reconstr Surg, 1967, 39(1): 76.
|
|
33 Bennett ML, Fleischer AB Jr, Chamlin SL. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation. Arch Dermatol, 2001, 137(9):1208-1213.
|
|
34 Argenta LC, David LR, Sanger C, et al. Advances in hemangioma evaluation and treatment. J Craniofac Surg, 2006, 17(4): 748-755.
|
|
35 Hansan Q, Tan ST, Xu B, et al. Effects of five commonly used glucocorticoids on haemangioma in vitro.Clin Exp Pharmacol Physiol, 2003, 30: 140-144.
|
|
36 Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg, 1999, 104(6): 1616-1623.
|
|
37 Argenta LC, David LR, Sanger C, et al. Advances in hemangioma evaluation and treatment. J Craniofac Surg, 2006, 17(4): 748-755.
|
|
38 Soloman LM, Wentzel HE, Greenberg MS. Studies in the mechanism of steroid vasoconstriction. J Invest Dermatol, 1965, 44: 129.
|
|
39 Sasaki GH, Pang CY, Wittliff JL. Pathogeneisis and treatment of infant skin strawberry hemangiomas. Clinical and studies in hormonal effects. Plast Reconst Surg, 1984, 73: 359.
|
|
40 Nichols GE, Gaffey MJ, Mills SE, et al. Lobular capillary hemangioma. An immunohistochemical study including steroid hormone receptor status. Am J Clin Pathol, 1992, 97(6): 770.
|
|
41 Yu S, Liu WY, Tang YM, et al. An experimental study on the mechanism of therapy for hemangioma with glucocorticoid. Zhonghua Yi Xue Za Zhi, 2005, 85(16): 1121-1124.
|
|
42 Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest, 1994, 93(6): 2357.
|
|
43 Yu S, Liu WY, Tang YM, et al. An experimental study on the mechanism of therapy for hemangioma with glucocorticoid. Zhonghua Yi Xue Za Zhi,2005, 85:1121-1124.
|
|
44 Matsuda S, Gomi F, Oshima Y, et al. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci, 2005, 46(3): 1062-1068.
|
|
45 Wang YS, Friedrichs U, Eicheler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol, 2002, 240(1): 42-48.
|
|
46 Kim I, Kim HG, So JN, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.Circ Res, 2000, 86(1): 24-29.
|
|
47 Holash J, Maisonpeirre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999, 284(5422): 1994-1998.
|
|
48 Bureau W, Van Slyke P, Jones J, et al. Chronic systemic delivery of angiopoietin-2 reveals a possible independent angiogenic effect. Am J Physiol Heart Circ Physiol, 2006, 291(2):1152.
|
|
49 Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res, 2001, 61(4):1255-1259.
|
|
50 Etoh T, Inoue H, Tnanka S, et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Res, 2001, 61(5):2145-2153.
|
|
51 Cerimele F, Brown LF, Bravo F, et al. Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor. Am J Pathol, 2003, 163 (4):1321-1327.
|
|
52 Féraud O, Mallet C, Vilgrain I. Expressional regulation of the angiopoietin-1 and -2 and the endothelial-specific receptor tyrosine kinase Tie2 in adrenal atrophy: A study of adrenocorticotropin-induced repair. Endocrinology, 2003, 144(10): 4607-4615.
|
|
53 Rogeli S, Klagsbrum M, Atzmon R, et al. Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol, 1989, 109(2): 823-831.
|
|
54 Razon MJ, Kraling BM, Mulliken JB, et al. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation, 1998, 5(2-3): 189.
|
|
55 Hasan Q, Ruger BM, Tan ST, et al. Clusterin/apoJ expression during the development of hemangioma. Hum Pathol, 2000,31(6): 691.
|
|
56 Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am, 2006,19: 345-351.
|
|
57 Chang HY, Yang X. Proteases for cell suicide: Functions and regulation of caspases. Microbiol Mol Biol Rev, 2000, 64(4): 821.
|
|
58 Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics, 2005,116(1): 38-45.
|